DONATE
GET INVOLVED
Clinical Trial Finder
Blaze a trail to better treatments and a cure for cystic fibrosis.
Due to COVID-19, restrictions regarding enrollment may be in place. Please contact study sites directly to learn about their screening and enrollment status.
As a clinical trial volunteer, you are paving the way for new treatments. Search or filter for trials that may be right for you, or learn more about what it means to be a trailblazer.
Showing 1-4 of 4 studies
As a clinical trial volunteer, you are paving the way for new treatments. Search for trials that may be right for you using the filter on the left, or learn more about what it means to be a trailblazer.
Showing 1-4 of 4 studies
-
Anti-InfectiveClosed to Enrollment
Inhaled Levofloxacin (MP-376) pediatric safety study , protocol number MPEX 206This study took place at multiple care centers across the U.S. It looked at the safety and tolerability of MP-376 Inhalation Solution, as well as how the body processes the drug, in children with CF.
-
Age:
6 Years to 16 Years
-
Mutation(s):
No Mutation Requirement
-
FEV1% Predicted:
25 to 95%
-
Number of Visits:
6
-
Length of Participation:
35 days
-
-
Anti-InfectiveCompleted with Results
Levofloxacin Inhalation Solution (Aeroquin™) compared to TOBI® in people with Cystic Fibrosis , protocol number MPEX 209This study looked at the safety and effectiveness of levofloxacin inhalation solution (AEROQUIN™), compared to tobramycin solution for inhalation (TIS in people with CF who had chronic Pseudomonas aeruginosa lung infection.
-
Age:
12 Years and Older
-
Mutation(s):
No Mutation Requirement
-
FEV1% Predicted:
25 to 85%
-
Number of Visits:
10
-
Length of Participation:
6 months
-
-
Anti-InfectiveCompleted with Results
Levofloxacin Inhalation Solution (Aeroquin™) compared to placebo in people with Cystic Fibrosis , protocol number MPEX 207This phase 3 study evaluated the safety and effectiveness of the aerosolized form of the antibiotic, levofloxacin, (AEROQUIN™) in people with CF.
-
Age:
12 Years and Older
-
Mutation(s):
No Mutation Requirement
-
FEV1% Predicted:
25 to 85%
-
Number of Visits:
6
-
Length of Participation:
2 months
-
-
Anti-InfectiveCompleted with Results
Inhaled Levofloxacin (MP-376) in CF Patients with P. aeruginosa (Phase 2 Study) , protocol number MPEX-204This phase 2 study evaluated the safety and effectiveness of a new inhaled antibiotic (MP-376 - a solution of levofloxacin) to control chronic pulmonary infections due to Pseudomonas aeruginosa in people with CF.
-
Age:
16 Years and Older
-
Mutation(s):
No Mutation Requirement
-
FEV1% Predicted:
25 to 75%
-
Number of Visits:
6
-
Length of Participation:
14 weeks
-
Showing 1-4 of 4 studies
- 1
Studies in this tool are multi-center studies facilitated by the Cystic Fibrosis Therapeutics Development Network. For a complete list of cystic fibrosis related studies, visit www.clinicaltrials.gov.
Related Topics
-
Questions to Ask When Considering a Specific Trial
Learn moreClinical trials that test potential drugs and therapies in people with cystic fibrosis are a major part of CF research. They take place at Cystic Fibrosis Foundation-accredited care centers all over the United States and enroll people with CF of all ages.
-
Patient Safety Is a Priority
Learn moreNothing is more important than patient safety in developing new treatments for cystic fibrosis. The U.S. government requires that all clinical trials are supervised for safety, and the Cystic Fibrosis Foundation adds additional measures to protect study volunteers.
-
Trikafta™
Learn moreThe following is a collection of information and news about Trikafta™, the triple-combination modulator therapy that was approved by the U.S. Food and Drug Administration on Oct. 21, 2019.
Sign up for clinical trial alerts
Get email updates about clinical trials that matter to you.
Check the Drug Development Pipeline
We’re attacking CF from every angle. Learn about the status of CF drugs in development.
Learn More